NCT03672253

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.

Conditions

• Multiple Myeloma
• Multiple Myeloma in Relapse
• Multiple Myeloma Progression

Interventions

Type	Name	Description
DRUG	CAR-T Re-treatment	Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.

Timeline

• Start date: 2018-07-26
• Primary completion: 2020-12-31
• Completion: 2020-12-31
• First posted: 2018-09-14
• Last updated: 2018-12-14

Locations

1 site across 1 country: China